- Arrowhead will receive $175 million upfront
- J&J will make a $75 million equity investment
- Janssen receives a worldwide exclusive license to the ARO-HBV program ... read more
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced... read more
Janssen Pharmaceutical today unveiled 96-week results from the pivotal Phase 3 AMBER study of Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,